Martine J. Piccart, M.D., Ph.D., is honorary professor of oncology at the Université Libre de Bruxelles (ULB) and scientific director of Brussels’ Jules Bordet Institute. Earning her medical degrees at ULB and oncology qualifications in New York and London, she is also a member of the Belgian Royal Academy of Medicine. She held presidencies of the European CanCer Organisation (ECCO), the European Organisation for the Research and Treatment of Cancer (EORTC), the European Society for Medical Oncology (ESMO). She served on the Boards of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), which nominated her as fellow of the AACR Academy in 2013.
In 1996, Prof. Martine Piccart, together with Prof. Aron Goldhirsch, created the Breast International Group (BIG) to foster collaboration and accelerate the development of better breast cancer treatments. The organization, chaired by Prof. Piccart, today unites 59 academic breast cancer research groups from around the world. BIG has more than 30 clinical trials under its umbrella at any one time, and several of BIG’s past studies are considered landmark and practice-changing. Prof. Piccart manages a number of high-profile international Phase 3 clinical trials including HERA (HERceptin Adjuvant), MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy), and ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation).
Prof. Piccart has been honored with numerous awards, including ASCO’s David A. Karnofsky Memorial Award, the Susan G. Komen’s Brinker Award for Scientific Distinction, the 2017 St. Gallen International Breast Cancer Award and most recently, the 2018 Prix Leopold Griffuel for translational and clinical research in France and the KNAW Bob Pinedo Cancer Care Award in November 2018 in Amsterdam, Netherlands. Prof. Piccart is author or co-author of over 530 publications in peer-reviewed journals.